UK To Speed New COVID-19 Drug Candidates Into Trials
Collaborative Project Hailed As ‘Transformative’
The first of six new compounds are expected to begin Phase II testing soon as part of the UK’s ACCORD initiative, a randomized platform trial bringing together government, industry and research organisations to find potential treatments for COVID-19.
You may also be interested in...
Moderna's vaccine has reached the requisite number of cases to trigger a Phase III interim analysis and Brazil allows SinoVac's trial to resume after a serious adverse event, but AstraZeneca's Calquence fails to show any benefit in hospitalized COVID-19 patients. Medicago and GSK also report vaccine progress and the RDIF strikes another production deal.
In addition to our daily in-depth coverage of key events relating to the coronavirus, we’re bringing you a periodic round-up of other pandemic developments. This edition covers events at the national, European and global level.
AstraZeneca will launch a global clinical trial for its blood cancer drug Calquence because it showed early respiratory promise in later-stage COVID-19 patients, those in intensive care units and on ventilators.